| Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C Y Tanaka, N Nishida, M Sugiyama, M Kurosaki, K Matsuura, N Sakamoto, ... Nature genetics 41 (10), 1105-1109, 2009 | 2768 | 2009 |
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection N Enomoto, I Sakuma, Y Asahina, M Kurosaki, T Murakami, C Yamamoto, ... New England Journal of Medicine 334 (2), 77-82, 1996 | 1314 | 1996 |
| Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A … N Enomoto, I Sakuma, Y Asahina, M Kurosaki, T Murakami, C Yamamoto, ... The Journal of clinical investigation 96 (1), 224-230, 1995 | 836 | 1995 |
| Inhibition of intracellular hepatitis C virus replication by synthetic and vector‐derived small interfering RNAs T Yokota, N Sakamoto, N Enomoto, Y Tanabe, M Miyagishi, S Maekawa, ... EMBO reports 4 (6), 602-608, 2003 | 425 | 2003 |
| Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection Y Asahina, K Tsuchiya, N Tamaki, I Hirayama, T Tanaka, M Sato, Y Yasui, ... Hepatology 52 (2), 518-527, 2010 | 332 | 2010 |
| Evidence-based clinical practice guidelines for Liver Cirrhosis 2020 H Yoshiji, S Nagoshi, T Akahane, Y Asaoka, Y Ueno, K Ogawa, ... Journal of gastroenterology 56 (7), 593-619, 2021 | 328 | 2021 |
| Specific inhibition of hepatitis C virus replication by cyclosporin A M Nakagawa, N Sakamoto, N Enomoto, Y Tanabe, N Kanazawa, ... Biochemical and biophysical research communications 313 (1), 42-47, 2004 | 278 | 2004 |
| α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C Y Asahina, K Tsuchiya, T Nishimura, M Muraoka, Y Suzuki, N Tamaki, ... Hepatology 58 (4), 1253-1262, 2013 | 267 | 2013 |
| Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis N Enomoto, M Kurosaki, Y Tanaka, F Marumo, C Sato Journal of General Virology 75 (6), 1361-1369, 1994 | 236 | 1994 |
| Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon‐β therapy M Kurosaki, N Enomoto, T Murakami, I Sakuma, Y Asahina, C Yamamoto, ... Hepatology 25 (3), 750-753, 1997 | 212 | 1997 |
| Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment K Koizumi, N Enomoto, M Kurosaki, T Murakami, N Izumi, F Marumo, ... Hepatology 22 (1), 30-35, 1995 | 196 | 1995 |
| Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection M Kurosaki, N Enomoto, F Marumo, C Sato Hepatology 18 (6), 1293-1299, 1993 | 178 | 1993 |
| Expressional screening of interferon‐stimulated genes for antiviral activity against hepatitis C virus replication Y Itsui, N Sakamoto, M Kurosaki, N Kanazawa, Y Tanabe, T Koyama, ... Journal of viral hepatitis 13 (10), 690-700, 2006 | 166 | 2006 |
| Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean N Nishida, H Sawai, K Matsuura, M Sugiyama, SH Ahn, JY Park, S Hige, ... PloS one 7 (6), e39175, 2012 | 165 | 2012 |
| Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors M Kurosaki, Y Tanaka, N Nishida, N Sakamoto, N Enomoto, M Honda, ... Journal of hepatology 54 (3), 439-448, 2011 | 147 | 2011 |
| Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α Y Tanabe, N Sakamoto, N Enomoto, M Kurosaki, E Ueda, S Maekawa, ... Journal of Infectious Diseases 189 (7), 1129-1139, 2004 | 137 | 2004 |
| Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C Y Asahina, N Izumi, N Enomoto, M Uchihara, M Kurosaki, Y Onuki, ... Journal of hepatology 43 (4), 623-629, 2005 | 132 | 2005 |
| Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial T Takehara, N Sakamoto, S Nishiguchi, F Ikeda, T Tatsumi, Y Ueno, ... Journal of gastroenterology 54, 87-95, 2019 | 120 | 2019 |
| JSH guidelines for the management of hepatitis B virus infection Drafting Committee for Hepatitis Management Guidelines and the Japan Society ... Hepatology Research 44, 1-58, 2014 | 116* | 2014 |
| Risk factors for long‐term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults K Ito, H Yotsuyanagi, H Yatsuhashi, Y Karino, Y Takikawa, T Saito, ... Hepatology 59 (1), 89-97, 2014 | 115 | 2014 |
